
The Longevity Letter #17: GRAIL's Cancer Test Just Failed Its Big Trial. Here's Why I Still Use It.
Despite sensational headlines about GRAIL's recent clinical trial missing its primary endpoint, the nuanced data, a booming competitive market, and new Medicare legislation prove that the multi-cancer early detection (MCED) field is actually advancing rapidly as a vital piece of comprehensive, personalized cancer screening.